Graham Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Graham Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$216K	Buy	92,427 +1,517	+2%	+$3.92K	0.01%	930
2025 Q4	$123K	Sell	90,910 -61,237	-40%	-$89.1K	﹤0.01%	1127
2025 Q3	$230K	Buy	152,147 +116,672	+329%	+$175K	﹤0.01%	988
2025 Q2	$41.2K	Sell	35,475 -89,326	-72%	-$118K	﹤0.01%	1250
2025 Q1	$198K	Buy	124,801 +66,855	+115%	+$144K	﹤0.01%	1138
2024 Q4	$176K	Buy	57,946 +15,760	+37%	+$51.6K	﹤0.01%	1099
2024 Q3	$155K	Buy	42,186 +30,721	+268%	+$112K	﹤0.01%	967
2024 Q2	$46.9K	Buy	+11,465	New	+$128K	﹤0.01%	985
2023 Q4	–	Sell	-10,600	Closed	-$213K	–	1388
2023 Q3	$213K	Buy	+10,600	New	+$269K	0.01%	843

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Graham Capital Management's ZNTL Position: Q1 2026 in Review

Graham Capital Management increased its Zentalis Pharmaceuticals (ZNTL) stake by 1.7% in Q1 2026, buying an estimated $3.92K and bringing the position to 92,427 shares worth $216K. The position accounts for 0.01% of the portfolio, ranked #930.

Graham Capital Management first reported a position in ZNTL in Q3 2023 and has held it in 9 quarters since. The position peaked at $230K in Q3 2025. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Graham Capital Management held 92,427 shares of Zentalis Pharmaceuticals worth $216K as of Q1 2026.
Graham Capital Management bought 1,517 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $3.92K.
Zentalis Pharmaceuticals made up 0.01% of Graham Capital Management's portfolio in Q1 2026, its #930 holding.
Graham Capital Management first reported a position in Zentalis Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
Graham Capital Management's Zentalis Pharmaceuticals position peaked at $230K in Q3 2025.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.